What is the prognosis and next steps for a patient with declining beta-human chorionic gonadotropin (beta-hCG) levels from 204 to 175 over 48 hours after a two-blastocyst transfer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Declining β-hCG After Blastocyst Transfer: Poor Prognosis

This pregnancy is failing and will result in a spontaneous abortion. A decline in β-hCG from 204 to 175 mIU/mL over 48 hours represents a 14% decrease, which falls far below the expected doubling pattern and indicates non-viable pregnancy 1.

Prognosis

  • The pregnancy is non-viable. In viable pregnancies after blastocyst transfer, β-hCG should rise by at least 66% over 48 hours 1. Your patient's β-hCG declined by 14%, which is diagnostic of pregnancy failure.

  • Initial β-hCG of 204 on day 12 post-transfer was already concerning. After blastocyst transfer, β-hCG levels >300 mIU/mL on day 16 post-retrieval predict ongoing pregnancy in 97% of cases 2. Your patient's level of 204 on day 12 (approximately day 14 post-retrieval) was suboptimal, and the subsequent decline confirms failure.

  • The declining pattern rules out viable intrauterine pregnancy. Research shows that β-hCG levels in viable pregnancies after blastocyst transfer average 334-383 IU/L by day 14-16 post-retrieval 3, and declining levels have 78% sensitivity for detecting pathologic pregnancies 1.

Immediate Management Steps

Determine pregnancy location to rule out ectopic pregnancy:

  • Obtain transvaginal ultrasound immediately to assess for intrauterine gestational sac or concerning adnexal findings 4. With β-hCG levels of 175-204 mIU/mL, an intrauterine gestational sac may not yet be visible, making this a "pregnancy of unknown location" 4.

  • Repeat β-hCG in 48 hours to confirm continued decline 4. A decline of less than 21% at 2 days or less than 60% at 7 days suggests retained trophoblasts or ectopic pregnancy 4.

  • Monitor until β-hCG reaches <5 mIU/mL to confirm complete spontaneous abortion without intervention 4. The rate of decline will depend on the starting concentration, with expected decline of 21-35% at 2 days and 60-84% at 7 days 4.

Critical Pitfall to Avoid

Do not assume this is a simple biochemical pregnancy without ruling out ectopic pregnancy. The declining β-hCG pattern can occur with both spontaneous abortion and ectopic pregnancy 4. Serial β-hCG monitoring combined with ultrasound surveillance is mandatory until either:

  • An intrauterine pregnancy is confirmed (then expectant management for miscarriage), or
  • β-hCG declines to <5 mIU/mL (confirming complete resolution), or
  • Clinical signs of ectopic pregnancy develop requiring intervention 4

Monitor for symptoms of ectopic pregnancy including abdominal pain, vaginal bleeding, or hemodynamic instability throughout the monitoring period 4.

Counseling for Future Cycles

  • Single embryo transfer remains the standard approach for future cycles despite this failure 5, 6, 7. There is no evidence that transferring two blastocysts improves cumulative live birth rates, and doing so significantly increases risks of multiple pregnancy complications 5, 6.

  • This failed cycle does not change the recommendation for single blastocyst transfer in subsequent attempts 6, 7. The ESHRE guidelines found no clear indication to favor double embryo transfer over single embryo transfer based on previous failed treatments 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Recurrent Implantation Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Failed Fertilization After ICSI

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.